Commentary

Video

Dr Schmid on Pembrolizumab Plus Chemotherapy in High-Risk, Early-Stage TNBC

Peter Schmid, MD, PhD, FRCP, discusses updated KEYNOTE-522 data showing that pembrolizumab plus chemotherapy improves EFS in early-stage TNBC.

What we haven’t [had] until now were the long-awaited overall survival data. This is only a key secondary end point, but it’s of course, from a patient perspective, the most important end point.”

Peter Schmid, MD, PhD, FRCP, professor, cancer medicine, Barts Cancer Institute, Queen Mary University of London, discusses the updated long-term overall survival (OS) results from the phase 3 KEYNOTE-522 trial (NCT03036488), which evaluated pembrolizumab (Keytruda) plus chemotherapy in patients with high-risk, early-stage triple-negative breast cancer (TNBC). Updated data were presented at the 2024 ESMO Congress.

The KEYNOTE-522 trial assessed pembrolizumab in combination with neoadjuvant chemotherapy followed by surgery and adjuvant pembrolizumab or placebo for patients with high-risk, early-stage TNBC. Schmid explains that earlier results showed that the addition of pembrolizumab to chemotherapy significantly increased pathologic complete response (pCR) rates by approximately 30.6%, with a pCR rate of 64.8% (95% CI, 59.9%-69.5%) vs 51.2% (95% CI, 44.1%-58.3%) in the placebo arm (estimated treatment difference, 13.6%; 95% CI, 5.4%-21.8%; P < .001).

At a median follow-up of 75.1 months (range, 65.9-84.0), the 60-month event-free survival (EFS) rate was statistically significant in favor of the pembrolizumab plus chemotherapy arm, at 81.2% compared with 72.2% in the placebo plus chemotherapy arm (HR, 0.65; 95% CI, 0.51-0.83), Schmid reports.

Additionally, the proportion of patients experiencing an EFS event, such as recurrence, progression, or death, was lower in the pembrolizumab group, at 20.3% compared with 29.2% in the placebo group. These results underscore the long-term benefit of pembrolizumab in combination with chemotherapy for patients with high-risk, early-stage TNBC, Schmid notes.

Furthermore, the 5-year OS rates were 86.6% (95% CI, 84.0%-88.8%) in the pembrolizumab arm vs 81.7% (95% CI, 77.5%-85.2%) in the placebo arm (HR, 0.66; 95% CI, 0.50-0.87; P = .00150). In total, 14.7% of patients in the pembrolizumab arm had an OS event vs 21.8% of those in the placebo arm.

Schmid concludes that these long-term data further solidify the role of pembrolizumab as part of the standard treatment strategy for this patient population.

Related Videos
Matthew P. Deek, MD
Guru P. Sonpavde, MD
David Rimm, MD, PhD
Suneel Kamath, MD
Kathleen N. Moore, MD, MS
Shaji Kumar, MD
Janaki Neela Sharma, MD
Karine Tawagi, MD,
Vered Stearns, MD
Peter Martin, MD